S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:OABI

OmniAb (OABI) Stock Price, News & Analysis

$5.42
+0.03 (+0.56%)
(As of 03/28/2024 ET)
Today's Range
$5.37
$5.50
50-Day Range
$5.13
$6.33
52-Week Range
$3.14
$6.72
Volume
410,830 shs
Average Volume
444,741 shs
Market Capitalization
$630.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.20

OmniAb MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.7% Upside
$9.20 Price Target
Short Interest
Healthy
5.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.61mentions of OmniAb in the last 14 days
Based on 32 Articles This Week
Insider Trading
Acquiring Shares
$1.17 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.98 out of 5 stars

Medical Sector

405th out of 938 stocks

Commercial Physical Research Industry

6th out of 10 stocks

OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
OmniAb's (OABI) "Buy" Rating Reaffirmed at Truist Financial
AI healthcare stock poised for 36,996% growth?
Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...
OmniAb (NASDAQ:OABI) Sees Unusually-High Trading Volume
OmniAb's (OABI) "Buy" Rating Reaffirmed at Benchmark
HC Wainwright Reiterates "Buy" Rating for OmniAb (NASDAQ:OABI)
Benchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)
OmniAb’s Market Potential and Financial Stability Affirm Buy Rating
Recap: OmniAb Q4 Earnings
OmniAb (OABI) Set to Announce Earnings on Wednesday
2 Speculative Small-Cap Biotech Stocks You Should Know About
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.20
High Stock Price Target
$11.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+67.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-50,620,000.00
Net Margins
-148.16%
Pretax Margin
-188.39%

Debt

Sales & Book Value

Annual Sales
$34.16 million
Book Value
$2.96 per share

Miscellaneous

Free Float
108,101,000
Market Cap
$637.00 million
Optionable
Optionable
Beta
-0.16
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 51)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 56)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 55)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 66)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller

OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

5 analysts have issued 1-year target prices for OmniAb's shares. Their OABI share price targets range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $9.20 in the next year. This suggests a possible upside of 69.7% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2024?

OmniAb's stock was trading at $6.17 at the start of the year. Since then, OABI shares have decreased by 12.2% and is now trading at $5.42.
View the best growth stocks for 2024 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OABI earnings forecast
.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.86%), Vanguard Group Inc. (4.86%), Private Management Group Inc. (2.27%), Dimensional Fund Advisors LP (2.26%), Villere ST Denis J & Co. LLC (1.85%) and Orchard Capital Management LLC (1.17%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners